Novartis Ag

Actelion Pharmaceuticals Ltd

Novartis Pharma Gmbh

Olivier Lambert

Lovelace Holman

Charles Tokunbo Adesuyi

Bruce Hamilton Lithgow

Michael Ausborn

Marc Riemenschnitter

Markus Ahlheim

Oskar Nagele

Holger Petersen

Rolf Loeffler

Jean-Daniel Bonny

Vitomir Vucenovic

Katrin Moser

The invention relates to stable pharmaceutical compositions comprising the compound of the below formula, or pharmaceutically acceptable salts, solvates, hydrates or morphological forms thereof 

Stable pharmaceutical compositions comprising a pyrimidine-sulfamide

The invention relates to stable pharmaceutical compositions comprising the compound of the below formula, or pharmaceutically acceptable salts, solvates, hydrates or morphological forms thereof. 

The present invention relates to improved microparticles comprising a somatostatin analog, a process of making said microparticles and to pharmaceutical compositions comprising the same.

Extended-release composition comprising a somatostatin derivative in microparticles

A pharmaceutical composition for parenteral administration of a somatostatin analog salt of aspartate, e.g. mono- or diaspartate, lactate, succinate, e.g. mono- or disuccinate, acetate, glutamate, e.g. mono- or diglutamate or citrate and water forming a gelling depot system after injection in contact with the body fluid.

Sustained release formulation comprising a somatostatin analogue

Microparticles consisting of (a) a matrix with a mixture of (a1) at least one hydrophobic, biologically degradable polymer and (a2) optionally at least one water-soluble polymer, (b) a pharmaceutical active ingredient distributed in the matrix, and (c) in addition at least one water-insoluble, surface-active substance from the group of lecithins and phospholipids, distributed in the matrix, and a three-phase emulsion process for their preparation.

Pharmaceutical microparticles

Stable pharmaceutical compositions include the compound of the below formula, or pharmaceutically acceptable salts, solvates, hydrates or morphological forms thereof: 

Pharmaceutical compositions comprising a somastatin analogue in the form of a liquid formulation for parenteral administration are disclosed.

Pharmaceutical composition comprising cyclic somatostatin analogues

Disclosed are microparticles comprising a somatostatin analogue embedded in a biocompatible pharmacologically acceptable polymer matrix for a long acting release and pharmaceutical compositions comprising such microparticles.

Growing community of inventors

Spechbach-le-Haut, France

Olivier Lambert